Tod Nestor
Analyst · H.C. Wainwright
Thank you, James. Net sales of $2.6 million for the first quarter of 2021 decreased 30.3% compared to sales of $3.8 million in the first quarter of 2020, driven by decreases in both commercial and military sales. When compared to $3.7 million in the fourth quarter of 2020, net sales were down 29.6% on a sequential basis, due in large part to decreased sales in our military business due to fluctuations in the timing of military orders and funding. Sales of our commercial products decreased mainly due to delays in the healthcare, education, commercial and industrial sectors because of the continuing macroeconomic slowdown and purchasing decisions being put on hold due to the COVID-19 pandemic. In addition, sales from our agency network were also lower, again, reflecting the impact from the COVID-19 pandemic. Sales of our military products decreased mainly due to availability of government funding for certain projects and the timing of orders. Sales to our top ten customers for the total company for the first quarter of 2021 decreased 25.1%, and sales to our top 20 customers decreased 29.3% compared to the first quarter of last year. From a mix perspective, military sales were $1.7 million for the first quarter of 2021, representing 65.4% of total net sales compared to $2 million or 54.1% of total net sales for the first quarter of 2020. Sales to commercial customers were $0.9 million in the first quarter of 2021, representing 34.6% of total net sales for the quarter, down from $1.7 million or 45.9% of total sales in the first quarter of 2020. The year-over-year decrease in commercial sales was mainly due to overall softness in the commercial market that began at the onset of the COVID-19 pandemic. Gross profit for the first quarter of 2021 was $600,000 compared with $1 million in the first quarter of 2020, a decrease of 46.4% year-over-year. On a sequential basis, gross profit declined compared to gross profit of $1.4 million in the fourth quarter of 2020. As a percentage of revenue, gross profit margin was 21% in the first quarter of 2021, reflecting less leverage of our fixed costs due to the lower sales compared to 27.3% in the first quarter of 2020. Adjusted gross profit margins for excess and obsolete, in transit and net realizable value inventory reserves resulted in the non-GAAP adjusted gross margins of 24.3% in the first quarter of 2021 compared to 25.2% in the first quarter of 2020 and 27.7% in the fourth quarter of 2020. We continue to expect our overall gross margins to be in the mid-20’s in the near-term and begin to approach the high 20’s percentage range as we introduce new products and make further improvements to our supply chain and negotiate better pricing to accompany our increased volumes. And depending upon sales mix and inventory valuations, we may see some fluctuations quarter-to-quarter. Operating expenses in the first quarter of 2021 were $2.9 million or 108.2% of sales compared to $2.3 million or 60.7% of sales in the first quarter of 2020, an increase of $557,000 or 24.3% year-over-year. The increase is mainly related to payroll expenses and R&D product testing associated with the development and launch of our UVCD products. Loss from operations in the first quarter of 2021 was $2.3 million compared to a loss from operations of $1.3 million in the first quarter of 2020, a year-over-year increase of $1 million. Sequentially, this compares to a loss from operations of $0.9 million in the fourth quarter of 2020; an increase of $1.4 million. Also, below the operating line, we had an $801,000 gain on the extinguishment of debt related to the forgiveness of our SBA PPP loan. The prior year quarter had an $873,000 gain related to the valuation of warrants. These warrants were reclassified to equity during the fourth quarter of 2020 and will not be subject to re-measurement in subsequent periods. Net loss for the first quarter of 2021 was $1.6 million or $0.45 per basic and diluted share-based on a 3.6 million fully diluted shares compared with a loss of $541,000 or $18 loss per basic and diluted share-based on 3.1 million fully diluted shares in the first quarter of 2020. On a sequential basis, we reported net income of $65,000 or $0.01 per basic and diluted share in the fourth quarter of 2020. Adjusted EBITDA, a non-GAAP measure, which excludes depreciation and amortization, interest expense, stock-based and other incentive comp was a loss of $2 million in the first quarter of 2021 compared with a loss of $1.1 million in the first quarter of 2020 and a loss of $800,000 in the fourth quarter of 2020. Now I would like to turn to the balance sheet. As of March 31, 2021, we had cash of $548,000 compared to $1.8 million at the end of 2020. Total debt as of March 31, 2021, was $3.4 million in short-term credit line borrowings. As a reminder, total availability is a measurement of our access to cash at a given point in time, and we believe this is a much more relevant metric than simply looking at cash balance or even net debt on the balance sheet. While excess borrowing availability on our credit facilities represents the difference between the maximum borrowing capacity and credit facilities and our actual borrowings under the credit facilities. As of March 31, 2021, we had total availability of $1.2 million, which was comprised of $548,000 of cash and $700,000 of excess borrowing availability under our credit facilities. Subsequent to the end of the quarter, we increased our total borrowing availability on our inventory line of credit by $500,000. In addition, at the end of April, we finalized a net $1.5 million bridge loan on favorable terms, increasing our liquidity as our core markets continue to rebound. During the first quarter of 2021, cash used in operations was $2.8 million, of which $700,000 was working capital. Cash used in investment activities was $109,000, and we generated $1.6 million in cash from financing activities. Once again, as we have mentioned previously, during our earnings calls, we would like to provide brief updates about the impact of the COVID-19 pandemic on our business. The company continues to operate under our customized COVID-19 contingency plan with employees that can alternately, primitively, work from in a plant or from their homes. James and I have already discussed the ongoing impact of the COVID-19 pandemic on our commercial business. The pandemic continues to impact our business, resulting in supply chain impacts, such as, first, increased wait times for products to arrive. Second, tremendously increased inbound and outbound freight and shipping costs; some of which can be passed along to customers. And now certain component shortages such as microprocessors, as well as other operational hurdles to overcome. Although we are launching our UVCD portfolio of products during the current pandemic as a good countervailing alternative to the pandemics impact on our commercial business, we very much see these products as fulfilling a permanent long-term market need for air and service disinfection in the workplace, consumer spaces and other social gathering locations.
.: